uploads/2019/05/pills-384846_1280-1.jpg

What Are Analysts Recommending for FOLD and PTLA in May?

By

Updated

Stock price movements

On May 21, Amicus Therapeutics (FOLD) closed at $12.31, 3.97% higher than the previous close, 48.85% higher than the 52-week low of $8.27, and 30.14% lower than the 52-week high of $17.62. The company’s market capitalization is $2.91 billion, and its PS (price-to-sales), PB (price-to-book), and PC (price-to-cash) ratios were 26.83x, 5.81x, and 6.65x, respectively.

Amicus Therapeutics’ 14-day RSI (relative strength index) is currently 42.05. The number of outstanding shares for the company is 236.66 million, while the short float ratio is 7.95%.

Article continues below advertisement

On May 21, Portola Pharmaceuticals (PTLA) closed at $29.08, 1.75% higher than the previous close, 96.35% higher than the 52-week low of $14.81, and 36.23% lower than the 52-week high of $45.60. The company’s market capitalization is $2.04 billion, and PS, PB, and PC ratios were 36.61x, 40.39x, and 6.32x, respectively.

Portola Pharmaceuticals’ 14-day RSI is currently 35.31. The number of outstanding shares for the company is 70.12 million, while the short float ratio is 18.39%.

Analysts’ recommendations and target price

The consensus ratings for both Amicus Therapeutics and Portola Pharmaceuticals are a “buy.” Wall Street analysts expect an upside potential of 52.72% for Amicus Therapeutics based on the company’s closing price on May 21. Analysts first reduced the company’s 12-month consensus target price from $18.78 in February to $18.67 in March but then raised it to $18.80 in April and May.

Out of 11 analysts covering Amicus Therapeutics, six recommend a “strong buy,” three recommend a “buy,” and two recommend a “hold.”

Wall Street analysts expect an upside potential of 42.37% for Portola Pharmaceuticals based on the company’s closing price on May 21. Analysts have increased the company’s 12-month consensus target price from $36.17 in February to $41.40 in March, April, and May.

Out of six analysts covering Portola Pharmaceuticals, three recommend a “strong buy,” one recommends a “buy,” and two recommend a “hold.” 

Advertisement

More From Market Realist